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Abstract  
Objective: To determine whether postpartum hemorrhage (PPH) protocols lead to decreases in maternal 
morbidity and mortality. 
Design: Systemic literature review.  
Methods: The clinical question investigated is whether the implementation of PPH protocols has 
measurable impact on maternal morbidity and mortality. Searches were done through PubMed using the 
keywords: “maternal hemorrhage postpartum protocol.” Studies were eliminated if they were more than 
10 years old, conducted outside the United States, published in a non-English language, used other 
animal subjects besides humans, used non-female subjects, if they did not answer the clinical question, 
or were review articles. Eventually, three cohort studies were included for analysis.  
Results: Cohort studies by Shields et al. and Skupski et al. were chosen for analysis as they met the 
inclusion/exclusion criteria for the proposed clinical question.  
Conclusions: All of the studies clearly demonstrate an improvement across a variety of measures of 
maternal morbidity.  
 
Introduction 
Obstetric hemorrhage (OH) is one of the leading causes of maternal mortality with a 27% 
prevalence worldwide. 1 OH is defined as excessive bleeding antepartum, intrapartum or postpartum. 
While developing countries carry the highest percentage of births affected by hemorrhage, developed 
countries are still affected with 16% of overall maternal deaths due to obstetric hemorrhage.1 Ironically, 
obstetric hemorrhage is considered to be one of the most preventable causes of maternal deaths2. For 
example, California and North Carolina found 70-93% of maternal deaths due to obstetric hemorrhage 
were preventable.3,4 
 Postpartum hemorrhage (PPH), a subset of obstetric hemorrhage, is responsible for significant 
maternal morbidity and mortality in the United States. PPH is defined as “excessive bleeding, ≥1,000mL, 
within the first 24 hours after birth, [and] up to 12 weeks postpartum,”5. It is relatively common for patients 
to receive a late diagnosis of PPH; this is due to both the difficulties of accurately estimating blood loss as 
well as the ability of healthy patients to remain asymptomatic until a significant volume of blood has been 
lost. 6 These difficulties in diagnosis help explain why protocol-driven care has been associated with 
improved outcomes in maternal mortality.  
In 2010, the Joint Commission on the Accreditation of Healthcare Organizations recommended 
that protocols regarding PPH should be implemented. In 2013, the American College of Obstetricians and 
Gynecologists (ACOG) and the Society for Maternal Fetal Medicine (MFM) along with several other 
groups formed The National Partnership for Maternal Safety (NPMS) which also recommended the 
adoption of postpartum hemorrhage protocols. 6 Currently, hospital protocols for intervention in PPH 
range from using pharmacologic therapies to massive transfusions and invasive procedures. However, 
within these therapies, there is still disagreement on who qualifies to receive each treatment as well as 
timing parameters and quantity of ordered treatments.2 One of the top priorities of NPMS is the 
implementation of a unit-standard obstetric hemorrhage protocol. In 2014, four years after the Joint 
Commission’s recommendations, a survey found only 67% of academic obstetric anesthesia units had a 
PPH protocol. 6 Kacmar et al. suspected the overall percentage of obstetric units nationwide with 
implemented PPH protocol was lower than 67% due to responder bias and the exclusion of community 
hospitals from the survey. 6 The effort begun by NPMS was intensified in 2015 through a partnership of 26 
organizations to implement The Alliance for Innovation on Maternal Health (AIM). 7 This is a “national 
data-driven maternal safety and quality improvement initiative” that incorporates approaches that have 
improved maternal safety in the United States, including the implementation of standardized procedures 
and protocols. 7 As of September 2017, there were 13 states and 3 health networks that were active in 
this program, which represented approximately 1.5 million births.5,7  
 PPH is a preventable condition that causes significant adverse outcomes potentially leading to 
death. Recent studies have suggested that the implementation of PPH protocols lead to decreased 
maternal mortality. The purpose of this review is to determine the impact of PPH protocols in hospitals on 
maternal hemorrhage and patient safety. 
 
PICO: 
Population: Women giving birth in hospital setting 
Intervention: Implementation of hospital hemorrhage protocols 
Comparison: No implementation of hospital hemorrhage protocols 
Outcome: Decreased maternal mortality 
 Clinical Question: 
Do female deliveries occurring in hospitals with protocols for maternal hemorrhage experience fewer 
maternal deaths in hospital deliveries than those occurring in hospitals without such protocols? 
 
Methods 
 An initial search of PubMed was performed in September 2018 using the search terms “maternal 
hemorrhage postpartum protocol.” One hundred ten articles were identified and no duplicates were found. 
They were then screened for eligibility. Exclusion criteria included articles published before 2008, non-
English language, animal subjects other than humans, non-female subjects, and articles with only 
abstracts. This yielded 70 articles. The remaining 70 articles were screened and articles were excluded if 
they did not answer the clinical question, were review articles or were research performed outside of the 
United States (Figure 1). Three cohort analyses qualified for this research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. PRISMA Chart 
Records identified through PubMed database searching  
(n = 110) 
 
 
Additional records identified through other sources  
(n =0) 
Sc
re
e
n
in
g 
Full-text articles excluded due to 
not addressing clinical question, 
review articles, or performed 
outside of the United States 
(n = 67) 
In
cl
u
d
e
d
 
El
ig
ib
ili
ty
 
Id
e
n
ti
fi
ca
ti
o
n
 
Records after duplicates removed 
(n = 110) 
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Inclusion Criteria: 
• Articles within the last 10 
years 
• Articles written in English 
• Human subjects 
• Female subjects 
 
Exclusion Criteria: 
• Articles before 2008 
• Articles not written in English 
• Animal subjects 
• Non-female subjects 
• Articles with only abstracts 
Full-text articles assessed for eligibility 
(n = 70 ) 
Studies included in qualitative synthesis  
(n = 3 ) 
Studies included in quantitative 
synthesis (meta-analysis) 
(n = 1 ) 
Search Terms: “maternal hemorrhage postpartum protocol” 
Results 
Study #1 
Comprehensive maternal hemorrhage protocols improve patient safety and reduce utilization of blood 
products. Shields et al. (2011) 
 
Study Objective:  To assess the effectiveness of instituting a comprehensive protocol for the treatment of 
maternal hemorrhage. 
Study Design: 
This was a retrospective and prospective cohort study performed at a medium-sized rural hospital 
in California with less than 3,000 deliveries per year. Before the protocol was initiated, there were three 
main phases of preparation: development, education, and team training. Development took place in 
November 2008 through January 2009, and included communication and actions needed between health 
care providers and clinical services and defining each hemorrhage stage. Stage 0 was a normal 
intrapartum and postpartum course. Stage 1 was bleeding greater than normal vaginal delivery (500mL) 
or cesarean section (1000mL). Stage 2 was bleeding that did not respond to conservative measures used 
in stage 1.  Stage 3 was continued bleeding >1500mL. Education took place February 2009 through April 
2009, and included feedback and suggestions that were implemented by protocol groups. Team training 
then consisted of nursing staff participating in a blood loss skills training, and labor and delivery 
simulations were performed. This was done so each member of the protocol team could practice and 
learn about their role and the role of others. The protocol was then implemented in May 2009. 
            The patient’s status and the interventions were grouped into 4 categories (stages 0-3). The 
protocol started when the patient was admitted to the labor and delivery floor. Each patient was evaluated 
on their risk for obstetric hemorrhage. They were put into a low risk, medium risk, or high risk category. 
Their risk category determined their level of “status alert” given to the blood bank; clot-tube requested, 
type and screen performed, and cross-matched blood initiated, respectively. Blood loss was measured by 
collection systems, weighing lap sponges and bed-ware. The nonblood fluids in the collection systems 
were subtracted. During the protocol, symptoms or abnormalities of vital signs escalated patients to stage 
2 or stage 3. These symptoms and abnormalities included: maternal heart rate >100bpm, blood pressure 
<85/45mmHg, shortness of breath, confusion, or agitation. 8 
            Those in stage 1 after delivery were assessed by nursing staff and if needed, given a single dose 
of an uterotonic agent after consulting with the physician. In stage 2, more healthcare personnel were 
recruited which included the obstetrician and on-call anesthesiologist and an obstetrical hemorrhage cart 
was brought to the patient’s room.  In stage 3, additional nursing staff and physicians (including surgeons 
and interventional radiology) were utilized. Additionally, fixed blood products in an obstetrical hemorrhage 
pack were prepared for release. This pack included units of fresh frozen plasma, packed red blood cells, 
platelets and cryoprecipitate. The goal was to maintain the patient’s labs as followed: HCT >24%, INR 
<1.4, platelets >50,000/uL, fibrinogen >100,000mg/dL, pH >7.2, base excess >-5, temperature >95°F, 
and a normal ionized calcium. 8 
            Stage 2 patients were monitored in labor and delivery for 24 hours postpartum and laboratory 
studies were taken at hour 1 and 4. Vital signs were taken more frequently during the first 6 hours after 
bleeding normalized. Stage 3 patients were monitored in the ICU with critical care, anesthesia, and 
obstetrics. 
            A survey was sent out to treating physicians and nursing staff 1 year after initiation of the protocol. 
The responses were evaluated using a 5-point system. The perceptions of physicians and staff were 
analyzed by paired t-test. The question on whether the protocol reduced the severity of hemorrhage was 
answered by comparing patients advancing to each stage before and after the protocol was initiated. The 
control period was 4 months in duration (985 deliveries), and interventional time was 12 months divided 
into 3 different 4-month blocks (2874 deliveries). 8 This data was analyzed by analysis of variance for 
changes in the number of patients treated at each stage8. Additionally, information on the patients who 
received blood products and units transfused were collected from the blood bank. The data for this was 
used comparing a 12-month period before the protocol (2939 deliveries) and a 12-month period after the 
protocol (2874 deliveries). This information was analyzed by t-test. 
Study Results: 
Amongst the 5813 deliveries during the study, the overall maternal hemorrhage rate was 3.6%. 
Combining only stage 2 and stage 3, the hemorrhage rate was 1.5%. The total number of patients in 
stage 1 or stage 3, before and after the protocol was initiated, did not change. However, after the protocol 
was initiated, there was more successfully treated patients in stage 1 and a decrease of patients entering 
stage 2, both having a P=0.02 and R2=0.95 (table 1). These findings are consistent with the goal of 
implementing education and training to allow better intervention and successful treatment of the patients. 
Table 1. Changes in stage of hemorrhage before and after protocol initiation8 
    
 
 
 
 
 
         The percentage of patients that had a greater blood loss than expected, stage 3, did not change 
during the study. However, before and after protocol, there was a reduction of total number of blood 
products transfused and average blood products used per month; 16.7 units/month pre-protocol and 6.3 
units/month post-protocol, P<0.01). The rate of disseminated intravascular coagulation (DIC) was 
reduced by 64%. 
            The study found less blood products were used even when readily available as patients 
experienced less overall blood loss demonstrated by the decrease in advancement of stages during the 
protocol. Additionally, with earlier intervention, fewer patients resulted in DIC. After one year of 
implementation, the survey results revealed increasing provider and staff comfort in hemorrhage situation 
as well as team communication during the situations, P<0.01. 
Study Critiques: 
This study had a relatively small number of deliveries compared to other hospitals in their system 
with over 3000 deliveries/year. However, those hospitals already have a protocol in place. Even though 
the study tried to calculate the pure blood products lost, there were most likely some over estimates due 
to these extra substances being weighed; extra fluids, membranes, bedding, and supplies. For the 
survey, it was only returned by 61% of physicians and 32% of nursing staff. So the results from these 
healthcare personnel may not represent the entire population involved in the protocol.  
Stage         Preprotocol                 Post-period 1             Post-period 4                Post-period 3 
 
1a                35% (22)b                            51% (25)                  69% (27)                   82% (49) 
 
2a                  53% (33)        45% (22)    18% (7)         8% (5) 
 
3            11% (7)         4% (2)    13% (5)    10% (6) 
__________________________________________________________________________________________________________________________________________ 
a P _ .02; b Numbers in parenthesis are total patients at that stage in that time period. 
Shields. Maternal hemorrhage protocol. Am J Obstet Gynecol 2011. 
The study explained the stages very well and each patient was assessed based on the criteria of 
each stage. Additionally, the results used a stricter p-value of 0.01 and rejected the null of the survey and 
study. Since the null was rejected, there was a difference pre and post-protocol hemorrhage outcomes 
and healthcare personnel confidence of involvement. The results of this study are consistent with the 
Joint Commission recommendation to establish a PPH protocol to reduce maternal hemorrhage rates and 
improve maternal safety. 
 
Study #2 
Comprehensive maternal hemorrhage protocols reduce the use of blood products and improve patient 
safety. Shields et al. (2015) 
 
Study Objective: To evaluate the effectiveness of a comprehensive maternal hemorrhage protocol in 
reducing the use of perinatal blood products and unplanned hysterectomies during childbirth. 
Study Design:  
This was a prospective cohort study of 32,059 deliveries by patients who were admitted for labor 
and delivery in a large health system. 9 
During a series of three 2-month time periods spread out over a year, data was collected from a 
clinical patient safety monitoring program for Dignity Health System. This health system involved 29 
hospitals with a total number of about 60,000 births per year; individual maternity units ranged in size 
from a rural unit with <200 deliveries per year to much larger urban units with over 6000 deliveries per 
year. A hemorrhage protocol with standardized interventions per patient risk level was given to all 29 
hospitals in 2010, and compliance with this protocol began to be assessed monthly in November 2011 by 
perinatal safety nurses and collected data was audited by perinatal nurse specialists. To qualify as 
“compliant,” all of the components from Table 2 had to be met. 
 
 
 
 
Table 2. Checklist for protocol compliance and data collection9 
□ Admission hemorrhage risk assessment completed 
□ Correct blood bank request requested, based on risk 
□ Blood and blood clots weighed per protocol 
□ Correct laboratory results obtained for stage 2 and 3 hemorrhage 
□ Were >2 uterotonics given without the medical doctor present 
□ Blood products administered according to protocol 
 
Quantity blood products are administered and which onesa 
Number of peripartum hysterectomiesa 
 
These items were used to assess compliance with the protocol. If 
any item was not checked, the care was deemed noncompliant. 
 
aAdditional data that were collected but not used to assess 
compliance with the protocol. 
 
 The protocol was initiated when the patient was admitted to labor and delivery, and interventions 
were mostly targeted towards postpartum hemorrhage. The first part of the protocol involved the use of 
graded assessments of patient acuity. Stage 0 and 1 were defined as “normal intrapartum and 
postpartum course” and “bleeding greater than expected”, respectively, where bleeding greater than 
expected was considered more than 500 mL for vaginal delivery or 1000 mL for cesarean section. These 
stages were distinguished from the higher acuity Stages 2 and 3 primarily by vital signs: a heart rate >110 
bpm, blood pressure ≤85/45 or >15% drop from baseline, or oxygen saturation ≤94% qualified patients for 
Stage 2 or 3. Additionally, clinical symptoms such as shortness of breath, confusion or agitation also 
prompted the clinician to categorize the patient in a higher stage. Bleeding that did not respond to 
conservative treatment was designated as Stage 2 while Stage 3 was defined as continued bleeding to 
exceed 1500 mL. 9  
 Standardized interventions were based on the stage the patient was in. For example, key parts 
of the Stage 1 hemorrhage interventions included a conference with the physician and a single dose of a 
supplemental uterotonic if uterine atony was suspected, while key components of Stage 2 interventions 
included the addition of more clinical staff to the patient’s care as well as the obstetrics hemorrhage cart 
(either at the bedside or in the operating room). In general, the system-wide protocols included the use of 
quantitative estimates of blood loss, continual assessment of patient bleeding status, fixed ratios of 
transfused blood products and the development of a designated obstetrics hemorrhage cart. Additionally, 
as patient acuity increased, defined target values were set for hematocrit, INR, platelet count, fibrinogen 
level, pH, temperature and serum calcium because these factors all influence coagulation. 
Three time periods were compared for data analysis with the first being a 2-month long baseline 
period in November-December 2011 before the protocol was implemented. This was followed by 
additional 2-month periods; one in April-June 2012, 5 months post-implementation, and one in 
September-October 2012 at 10 months post-implementation. Initial data interpretation involved 
comparison of the peripartum hysterectomy rate between 2011 and 2012; data was analyzed by t-test. 
The use of blood products was similarly compared across time points.  
Study Results:  
Throughout the study, the health system showed improved compliance in its implementation of 
the maternal hemorrhage protocol. At the start, the compliance rate was 54%; this increased to 80% by 
period 2. As the protocol compliance increased, more patients were correctly recognized as being in 
higher risk categories and higher stages of active hemorrhage. For example, the number of patients who 
were placed into “stage 3” hemorrhage increased by 60% from the baseline time point to the last 
measurement. At the same time that overall protocol compliance increased (54% at baseline to 80% at 
the end of the study), the overall use of blood products was significantly reduced, by 25.9% per 1000 
births (P <0.01). This correlated with a 14.8% reduction in the number of patients who had both obstetric 
hemorrhage and peripartum hysterectomy, although this decrease was not found to be statistically 
significant (P = 0.2).9  
Study Critique  
Strengths included the large number of research subjects. Using over 32,000 births in this study 
provided a robust data set.  
Limitations of this study are that even after more than a year spent on implementing the maternal 
hemorrhage protocol, up to 20% of births in this hospital systems were not in compliance with the 
protocol. This affects the result validity. Additionally, the authors note that there were difficulties with 
accurately estimating maternal blood loss, so much so that specific skills workshops were added to the 
implementation period. Inter- and intra-observer variability likely caused some patients to be mis-
categorized within the protocol, which again would affect the validity of the study’s results. 
 Study #3 
Improvement in Outcomes of Major Obstetric Hemorrhage Through Systematic Change. Skupski  et al. 
(2017) 
 
Study Objective: To investigate the effect of a multiyear systematic institutional effort to improve the care 
of women with obstetric hemorrhage of >1500 mL. 
Study Design:  
This was a retrospective cohort study of 57,694 births at a tertiary care facility that included a 
level IIIB neonatal intensive care unit, level III maternity care and level I trauma.10 From 2000 to 2014, 
baseline conditions, morbidity and mortality were compared across three time periods for women who 
had documented major obstetric hemorrhage (estimated peripartum blood loss of >1500 mL). The data 
that was collected about patient baseline condition included age, multiparity, prior cesarean delivery, and 
morbidly adherent placenta. Measures of morbidity included the presence of: hypothermia, defined as 
less than 38°C; acidemia, defined as maternal arterial pH less than 7.32; coagulopathy; pulmonary 
embolus; pneumonia; organ damage; and the transfusion of 4 or more units of packed red blood cells. 
The time periods compared included January 2000 to December 2001 (period 1), January 2002 to August 
2005 (period 2), and September 2005 to December 2014 (period 3).10 There were 5,811 births in period 
1; 12,912 births in period 2; and 38,971 births in period 3. Hemorrhage cases were collected to be 
entered into the research database by the authors and validation of data was performed by a senior 
author.  
The management protocol contained a variety of interventions including the development of an 
obstetric rapid response team and a massive transfusion protocol; standard evaluation and treatment of 
postpartum bleeding to include collection of frequent vital signs, application of uterine massage, and 
common use of arterial blood gas measurement; frequent trainings and emergency drills; and the 
development of clinical pathways regarding the diagnosis of placenta previa and accreta. Screening for 
placenta previa took place in the second trimester and all patients with positive findings on ultrasound 
received a second scan at 30-32 weeks of gestation. Maternal-fetal medicine was consulted if patients 
had continued placenta previa or suspected placenta accreta at their second scan, with the goal of a 
scheduled early delivery between 35 and 36 weeks for placenta accreta without bleeding and 38 weeks 
for placenta previa without bleeding. The presence of bleeding in conjunction with abnormal placenta led 
to earlier delivery. Additionally, they recommended a planned cesarean hysterectomy for patients with a 
diagnosis of placenta increta or percreta.  
Data from the different time periods were analyzed by Fisher exact test, Wilcoxon rank-sum test 
and unpaired t-test.  
Study Results 
 While the rate of obstetric hemorrhage increased over the course of the study from 2.1 
cases/1000 births in period 1 to 5.3 cases/1000 births in period 3, a decrease in measures of morbidity 
was found over the same time span. Improvements included a decrease in cases of maternal 
hypothermia, acidemia and coagulopathy between period 3 vs. period 1 (P = <0.001 for all). There was 
also an improvement in mortality in period 3 compared to period 1 (P = 0.001).10  
Study Critique 
 Strengths of this study included the long time period that was investigated. Data showed trends 
over the span of 14 years, enough time to show evidence of how changes in practice were affecting 
outcome.  
 Limitations included the fact that the study took place at a single hospital. Also, some planned 
components of their protocol to improve obstetric hemorrhage outcomes were not yet in place during the 
time they reported, including the implementation of quantitative blood loss techniques.  
 
Discussion 
Maternal hemorrhage is a serious condition with significant impact on morbidity and mortality 
during labor and in the postpartum period. After reviewing all three articles, the results showed that PPH 
protocols reduced the maternal hemorrhage rates along with increasing the overall safety of the patient.  
Some strength and weakness in our research included sample size, variety of protocols used, 
estimated blood loss, and different facilities in which the studies took place. Study 1 had a smaller sample 
size compared to the other two studies reviewed. However, this study was chosen to compare and 
contrast a protocol once it was implemented in a single hospital. There were different protocols compared 
within our articles, so drawing conclusions from one protocol versus another protocol made it harder to 
extrapolate PPH protocols as a whole. However, despite the variability in the protocols used within these 
three articles, all three studies revealed an improved outcome in maternal health after PPH protocols 
were implemented. Additionally, each study had to determine the amount of blood loss for each patient. 
Study 3 measured blood loss by qualitative means whereas the other two studies measured blood loss 
quantitatively.  Patients were from different areas within the United States but all found an improvement 
with PPH protocols which helped eliminate geographic area as a confounding variable.  
Shields et al (2011) found that after the implementation of a PPH protocol, there was a reduction 
in the total number of blood products transfused (P<0.01). They also were able to successfully keep more 
patients in a lower acuity stage, finding a decrease of patients entering stage 2 (P=0.02), as well as a 
decreased rate of DIC. Shields et al (2015) also found that as overall protocol compliance increased 
within a health care system, the use of blood products was reduced by 25.9% (P <0.01). There was also 
a reduction in the number of patients with concomitant obstetric hemorrhage and peripartum 
hysterectomy, but this decrease was not found to be statistically significant (P = 0.2). Skupski et al (2017) 
reported that despite an increase in rates of obstetric hemorrhage over a period of 14 years, a decrease 
in measures of morbidity and mortality was found over this same time span as a PPH protocol was 
implemented in a large tertiary care center. Mortality decreased (P=0.001) along with cases of maternal 
hypothermia, acidemia and coagulopathy (P = <0.001). Overall, each study showed statistically significant 
improvements in a wide range of maternal peripartum health markers.  
It has been shown that so-called “near miss” events (blood loss of ≥ 1500 mL) occur in about 
15% of patients with postpartum hemorrhage. Studies have also shown that many of the negative 
outcomes of maternal hemorrhage are preventable, and several recent efforts have been made to 
quantify the effect that protocol-driven care has on episodes of hemorrhage in the peripartum period.  
 
Conclusion 
PPH protocols are effective and efficient interventions with proven safety benefits and low risk of 
complications. This sort of stepped-care plan has the potential to improve quality of care in a wide variety 
of hospital settings, including both low-volume rural hospitals and large tertiary care centers in urban 
areas. A negative effect of implementing such protocol may be the time it takes to organize it and 
train/educate healthcare professionals in their role during the protocol. Additionally, there may be some 
concern on overuse of transfusions.  
There are currently a variety of different postpartum hemorrhage protocols between facilities. 
From our research, we know that PPH protocols are beneficial in maternal health, but we did not 
investigate protocol specifics. A recommendation for future research would be looking into specific 
protocols to determine if one is superior to another. In the future, if one protocol is superior to others, we 
believe this would be the most beneficial with implementation of a protocol.  It seems reasonable to 
assume that PPH protocols are a low-cost intervention as they utilize resources already in place, just in a 
more organized manner. However, our research did not incorporate data on the cost of implementing a 
PPH protocol in either a single institution or across a large health system. This would also be a 
reasonable area for future research.  
 
Acknowledgments 
We would like to thank Dr. Abby Massey and Carolyn Schubert for their support and guidance throughout 
this project. 
  
References 
1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systemic analysis. The 
Lancet Global Health. 2014;2(6):e323-333. doi:10.1016/ S2214-109X(14)70227-X. 
2. Obrien KL, Shainker SA, Lockhart EL. Transfusion Management of Obstetric Hemorrhage. 
Transfusion Medicine Reviews. May 2018. doi:10.1016/j.tmrv.2018.05.003. 
3. Berg CJ, Harper MA, Atkinson SM, et al. Preventability of pregnancy-related deaths: results of a 
state-wide review. Obstetrics & Gynecology. 2005;106 (6):1228–1234. 
doi:10.1097/01.AOG.0000187894.71913.e8. 
4. Main EK, Mccain CL, Morton CH, Holtby S, Lawton ES. Pregnancy-Related Mortality in California. 
Obstetrics & Gynecology. 2015;125(4):938-947. doi:10.1097/aog.0000000000000746. 
5. The American College of Obstetricians and Gynecologists. ACOG Expands Recommendations to 
Treat Postpartum Hemorrhage. https://www.acog.org/About-ACOG/News-Room/News-
Releases/2017/ACOG-Expands-Recommendations-to-Treat-Postpartum-Hemorrhage. Published 
September 21, 2017 
6. Kacmar RM, Mhyre JM, Scavone BM, Fuller AJ, Toledo P. The Use of Postpartum Hemorrhage 
Protocols in United States Academic Obstetric Anesthesia Units. Anesthesia & Analgesia. 
2014;119(4):906-910. doi:10.1097/01.aoa.0000469465.38369.e9 
7. AIM. Alliance for Innovation on Maternal Health Program. 
https://safehealthcareforeverywoman.org/aim-program/. Published 2018 
8. Shields L, Smalarz K, Reffigee L, Mugg S, Burdumy T, Propst M. Comprehensive maternal 
hemorrhage protocols improve patient safety and reduce utilization of blood products. American 
Journal of Obstetrics and Gynecology. 11AD;205(4):368.e1-368.e8. doi:10.1016/j.ajog.2011.06.084. 
9. Shields L, Wiesner S, Fulton J, Pelletreau B. Comprehensive maternal hemorrhage protocols reduce 
the use of blood products and improve patient safety. American Journal of Obstetrics and 
Gynecology. 2015;212(3):272-280. doi:10.1016/j.ajog.2014.07.012. 
10. Skupski DW, Brady D, Lowenwirt IP, et al. Improvement in Outcomes of Major Obstetric Hemorrhage 
Through Systematic Change. Obstetrics & Gynecology. 2017;130(4):770-777. 
doi:10.1097/aog.0000000000002207. 
